CoChat
Cited by 68

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

The state of GPCR research in 2004

The Nature Reviews Drug Discovery GPCR Questionnaire Participants., Ellis, Clare · 2004 · Nature Reviews Drug Discovery

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd1458

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 210

  1. Decaillot, F. M. et al. Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nature Struct. Biol. 10, 629–636 (2003). · DOI
  2. Lembo, P. M. et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nature Neurosci. 5, 201–209 (2002). · DOI · Paper page
  3. Lu, Z. L., Saldanha, J. W. & Hulme, E. C. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci. 23, 140–146 (2002). · DOI
  4. Yamaguchi, T. Molecular constituents and phosphorylation-dependent regulation of the post-synaptic density. Mass Spec. Rev. 21, 266–286 (2002). · DOI · Paper page
  5. Gross, C. et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416, 396–400 (2002). · DOI · Paper page
  6. Ghanouni, P. et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. J. Biol. Chem. 276, 24433–24436 (2001). · DOI · Paper page
  7. Janetopoulos, C., Jin, T. & Devreotes, P. Receptor-mediated activation of heterotrimeric G-proteins in living cells. Science 291, 2408–2411 (2001). · DOI
  8. Vilardaga, J. P., Bunemann, M., Krasel, C., Castro, M. & Lohse, M. J. Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nature Biotechnol. 21, 807–812 (2003). · DOI · Paper page
  9. Yi, T. M., Kitano, H. & Simon, M. I. A quantitative characterization of the yeast heterotrimeric G protein cycle. Proc. Natl Acad. Sci. USA 100, 10764–10769 (2003). · DOI · Paper page
  10. Tunaru, S. et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nature Med. 9, 352–355 (2003). · DOI · Paper page
  11. Kieffer, B. L. Opioids: first lessons from knockout mice. Trends Pharmacol. Sci. 20, 19–26 (1999). · DOI · Paper page
  12. Roques, B. P., Daugé, V., Gacel, G. & Fournié-Zaluski, M. C. in Biological Psychiatry, Developments in Psychiatry. Vol. 7 (eds Shagass, C. et al.) 287–289 (Elsevier, New York, 1985).
  13. Chang, K. J., Porreca, F. & Woods, J. H. The Delta Receptor (Marcel Dekker, New York, 2004).
  14. Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21, 90–113 (2000). · DOI · Paper page
  15. Bockaert, J. et al. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett. 546, 65–72 (2003). · DOI · Paper page
  16. Xiang, Y. & Kobilka, B. The PDZ-binding motif of the β2-adrenoceptor is essential for physiologic signaling and trafficking in cardiac myocytes. Proc. Natl Acad. Sci. USA 100, 10776–10781 (2003). · DOI
  17. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001). · DOI · Paper page
  18. Seifert, R., Wenzel-Seifert, K. & Kobilka, B. K. GPCR–Gα fusion proteins: molecular analysis of receptor–G-protein coupling. Trends Pharmacol. Sci. 20, 383–389 (1999). · DOI
  19. Wenzel-Seifert, K., Hurt, C. M. & Seifert, R. High constitutive activity of the human formyl peptide receptor. J. Biol. Chem. 273, 24181–24189 (1998). · DOI
  20. Seifert, R., Lee, T. W., Lam, T. L. & Kobilka, B. K. Reconstitution of β2-adrenoceptor–GTP-binding protein interaction in Sf9 cells. High coupling efficiency in a β2-adrenoceptor–Gsα fusion protein. Eur. J. Biochem. 255, 369–382 (1998). · DOI
  21. Seifert, R. et al. Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J. Pharmacol. Exp. Ther. 305, 1104–1115 (2003). · doi:10.1124/jpet.103.049619
  22. Wenzel-Seifert, K., Arthur, J. M., Liu, H. Y. & Seifert, R. Quantitative analysis of formyl peptide receptor coupling to Giα1, Giα2, and Giα3 . J. Biol. Chem. 274, 33259–33266 (1999). · DOI
  23. Houston, C., Wenzel-Seifert, K., Bürckstümmer, T. & Seifert, R. The human histamine H2-receptor couples more efficiently to Sf9 insect cell Gs-proteins than to insect cell Gq-proteins: limitations of Sf9 cells for the analysis of receptor/G-protein coupling. J. Neurochem. 80, 678–696 (2002). · DOI
  24. Gille, A. & Seifert, R. 2′(3′)-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors. J. Biol. Chem. 278, 12672–12679 (2003). · DOI
  25. Gille, A. & Seifert, R. Low-affinity interactions of BODIPY-FL-GTPγS and BODIPY-FL-GppNHp with Gi- and Gs-proteins. Naunyn-Schmiedeberg's Arch. Pharmacol. 368, 210–215 (2003). · DOI
  26. Gille, A. et al. Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J. Biol. Chem. 279, 19955–19969 (2004). · DOI
  27. Seifert, R., Wenzel-Seifert, K., Gether, U. & Kobilka, B. K. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J. Pharmacol. Exp. Ther. 297, 1218–1226 (2001).
  28. Furukawa, H. et al. Conformation of ligands bound to the muscarinic acetylcholine receptor. Mol. Pharmacol. 62, 778–787 (2002). · doi:10.1124/mol.62.4.778
  29. Luca, S. et al. The conformation of neurotensin bound to its G protein-coupled receptor. Proc. Natl Acad. Sci. USA 100, 10706–10711 (2003). · DOI · Paper page
  30. Banères, J. -L. & Parello, J. Structure-based analysis of GPCR function: conformational adaptation of both agonist and receptor upon leukotriene B4 binding to recombinant BLT1. J. Mol. Biol. 329, 815–829 (2003). · DOI · Paper page
  31. Peleg, G., Ghanouni, P., Kobilka, B. K. & Zare, R. N. Single-molecule spectroscopy of the β2 adrenergic receptor: observation of conformational substates in a membrane protein. Proc. Natl Acad. Sci. USA, 98, 8469–9474 (2001). · DOI
  32. Seifert, R. & Wenzel-Seifert, K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 366, 381–416 (2002). · DOI · Paper page
  33. Seifert, R., Gether, U., Wenzel-Seifert, K. & Kobilka, B. K. Effects of guanine, inosine and xanthine nucleotides on β2-adrenergic receptor/Gs interactions: evidence for multiple receptor conformations. Mol. Pharmacol. 56, 348–358 (1999). · DOI
  34. Steinberg, S. F. & Brunton, L. L. Compartmentation of G-protein-coupled signaling pathways in cardiac myocytes. Annu. Rev. Pharmacol. Toxicol. 41, 751–773 (2001). · DOI · Paper page
  35. Luttrell, L. M. & Lefkowitz, R. J. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell. Sci. 115, 455–465 (2002). · DOI · Paper page
  36. George, S. R., O'Dowd, B. F. & Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Rev. Drug Discov. 1, 808–820 (2002). · DOI · Paper page
  37. Angers, S., Salahpour, A. & Bouvier, M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu. Rev. Pharmacol. Toxicol. 42, 409–435 (2002). · DOI · Paper page
  38. Bockaert, J. & Pin, J. P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18, 1723–1729 (1999). · DOI · Paper page
  39. Gbahou, F. et al. Protean agonism at histamine H3 receptors in vitro and in vivo. Proc. Natl Acad. Sci. USA 100, 11086–11091 (2003). · DOI
  40. Leff, P., Scaramellini, C., Law, C. & McKechnie, K. A three-state receptor model of agonist action. Trends Pharmacol. Sci. 18, 355–362 (1997). · doi:10.1016/s0165-6147(97)90664-7
  41. Kenakin, T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24, 346–354 (2003). · DOI · Paper page
  42. Adan, R. A. H. & Kas, M. J. H. Inverse agonism gains weight. Trends Pharmacol. Sci. 24, 315–321 (2003). · DOI
  43. Smit, M. J. et al. Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors. Proc. Natl Acad. Sci. USA 93, 6802–6807 (1996). · DOI · Paper page
  44. Kjelsberg, M. A., Cotecchia, S., Ostrowski, J., Caron, M. G. & Lefkowitz, R. J. Constitutive activation of the α1B adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J. Biol. Chem. 267, 1430–1433 (1992). · DOI · Paper page
  45. Chen, G. et al. Use of constitutive G-protein-coupled receptor activity for drug discovery. Mol. Pharmacol. 57, 125–134 (2000). · DOI
  46. Sakmar, T. P., Menon, S. T., Marin, E. P. & Awad, E. S. Rhodopsin: insights from recent structural and mutagenesis studies. Annu. Rev. Biophys. Biomol. Struct. 31, 443–484 (2002). · DOI · Paper page
  47. Swaminath, G. et al. Sequential binding of agonists to the β2 adrenoceptor. Kinetic evidence for intermediate conformational states. J. Biol. Chem. 279, 686–691 (2004). · DOI · Paper page
  48. Whistler, J. L., Chuang, H. H., Chu, P., Jan, L. Y. & von Zastrow, M. Functional dissociation of μ-opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23, 737–746 (1999). · DOI · Paper page
  49. Willins, D. L. et al. Serotonergic antagonist effects on trafficking of serotonin 5-HT2A receptors in vitro and in vivo. Ann. NY Acad. Sci. 861, 121–127 (1998). · DOI
  50. Seifert, R. & Wenzel-Seifert, K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Arch. Pharmacol. 366, 381–416 (2002). · DOI · Paper page
  51. Azzi, M. et al. β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl Acad. Sci. USA 100, 11406–11411 (2003). · DOI · Paper page
  52. Morello, J. -P. et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest. 105, 887–895 (2000). · DOI · Paper page
  53. Kelley, M. et al. Distinct interaction of human and guinea pig histamine H2-receptor with guanidine-type agonists. Mol. Pharmacol. 60, 1210–1225 (2001). · DOI
  54. Liang, X., Lu, Y., Wilkes, M., Neubert, T. A. & Resh, M. D. Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J. Biol. Chem. 278, 21655–21662 (2003). · DOI · Paper page
  55. Neve, K. A. et al. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Mol. Pharmacol. 60, 373–381 (2001). · DOI
  56. Ballesteros, J. A., Shi, L. & Javitch, J. A. Structural mimicry in G-protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure–function analysis of rhodopsin-like receptors. Mol. Pharmacol. 60, 1–19 (2001). · doi:10.1124/mol.60.1.1 · Paper page
  57. Malherbe, P. et al. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. Mol. Pharmacol. 64, 823–832 (2003). · DOI
  58. Bissantz, C., Bernard, P., Hibert, M. & Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins 50, 5–25 (2003). · DOI · Paper page
  59. Tsamis, F. et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77, 5201–5208 (2003). · DOI · Paper page
  60. Archer, E., Maigret, B., Escrieut, C., Pradayrol, L. & Fourmy, D. Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? Trends Pharmacol. Sci. 24, 36–40 (2003). · DOI
  61. Allen, S., Rigby-Singleton, S. M., Harris, H., Davies, M. C. & O'Shea, P. Measuring and visualizing single molecular interactions in biology. Biochem. Soc. Transactions 31, 1052–1057 (2003). · doi:10.1042/bst0311052
  62. MacKinnon, R. Potassium channels. FEBS Lett. 555, 62–65 (2003). · DOI · Paper page
  63. Dutzler, R., Campbell, E. B. & MacKinnon, R. Gating the selectivity filter in ClC chloride channels. Science 300, 108–112 (2003). · DOI · Paper page
  64. Bass, R. B. et al. The structures of BtuCD and MscS and their implications for transporter and channel function. FEBS Lett. 555, 111–115 (2003). · doi:10.1016/s0014-5793(03)01126-8
  65. White, J. F., Trinh, L. B., Shiloach, J. & Grisshammer, R. Automated large-scale purification of a G-protein-coupled receptor for neurotensin. FEBS Lett. 564, 289–293 (2004). · doi:10.1016/s0014-5793(04)00195-4
  66. Lundstrom, K. Semliki Forest virus vectors for rapid and high-level expression of integral membrane proteins. Biochim. Biophys. Acta 1610, 90–96 (2003). · DOI
  67. Kobilka, B. K. Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. Anal. Biochem. 231, 269–271 (1995). · DOI · Paper page
  68. Banères, J. L. et al. Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J. Mol. Biol. 329, 801–814 (2003). · DOI
  69. Bertin, B., Freissmuth, M., Jockers, R., Strosberg, A. D. & Marullo, S. Cellular signaling by an agonist-activated recepto/Gsα fusion protein. Proc. Natl Acad. Sci. USA 91, 8827–8831 (1994). · DOI
  70. Martini, L. et al. NK1 receptor fused to β-arrestin displays a single-component, high-affinity molecular phenotype. Mol. Pharmacol. 62, 30–37 (2002). · DOI
  71. Fernandez, C. & Wüthrich, K. NMR solution structure determination of membrane proteins reconstituted in detergent micelles. FEBS Lett. 555, 144–150 (2003). · DOI
  72. Gether, U., Lin, S. & Kobilka, B. K. Fluorescent labeling of purified β2 adrenergic receptor. Evidence for ligand-specific conformational changes. J. Biol. Chem. 270, 28268–28275 (1995). · DOI · Paper page
  73. Abramson, J. et al. Structure and mechanism of the lactose permease of Escherichia coli. Science 301, 610–615 (2003). · DOI · Paper page
  74. Palanche, T. et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J. Biol.Chem. 276, 34853–34861 (2001). · DOI
  75. Jordan, B. A. & Devi, L. A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697–700 (1999). · DOI · Paper page
  76. Bowery, N. G. Mammalian γ-aminobutyric acid (B) receptors: structure and function. Pharmacol. Rev. 54, 247–264 (2002). · DOI · Paper page
  77. Wenzel-Seifert, K. & Seifert, R. Molecular analysis of β2-adrenoceptor coupling to Gs-, Gi-, and Gq-proteins. Mol. Pharmacol. 58, 954–966 (2000). · DOI
  78. Gille, A., Liu, H. Y., Sprang, S. R. & Seifert, R. Distinct interactions of GTP, UTP, and CTP with Gs-proteins. J. Biol. Chem. 277, 34434–34442 (2002). · DOI
  79. Noble, F. & Roques, B. P. in Understanding G-Protein-Coupled Receptors and their role in the CNS (eds Pangalos, M. & Davies, C.) 242–263 (Oxford Univ., Oxford, 2002). · doi:10.1093/oso/9780198509165.003.0014
  80. Marshall, F. H., Jones, K. A., Kaupmann, K. & Bettler, B. GABAB receptors — the first 7TM heterodimers. Trends Pharmacol. Sci. 20, 396–399 (1999). · DOI · Paper page
  81. Nelson, G. et al. Mammalian sweet taste receptors. Cell 106, 381–390 (2001). · DOI · Paper page
  82. Sexton, P. M., Albiston, A., Morfis, M. & Tilakaratne, N. Receptor activity modifying proteins. Cell. Signal. 13, 73–83 (2001). · DOI · Paper page
  83. Ramsay, D., Kellett, E., McVey, M., Rees, S. & Milligan, G. Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem. J. 365, 429–440 (2002). · DOI · Paper page
  84. Mercier, J. F., Salahpour, A., Angers, S., Breit, A. & Bouvier, M. Quantitative assessment of β1- and β2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J. Biol. Chem. 277, 44925–44931 (2002). · DOI · Paper page
  85. Terrillon, S. et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol. Endocrinol. 17, 677–691 (2003). · DOI · Paper page
  86. Hague, C., Uberti, M. A., Chen, Z., Hall, R. A. & Minneman, K. P. Cell surface expression of α1D-adrenergic receptors is controlled by heterodimerization with α1B-adrenergic receptors. J. Biol. Chem. 279, 15541–15549 (2004). · DOI · Paper page
  87. Jones, K. A. et al. GABAB receptors function as a heteromeric assembly of the subunits GABABR1 and GABABR2. Nature 396, 674–679 (1998). · DOI · Paper page
  88. White, J. H. et al. Heterodimerization is required for the formation of a functional GABAB receptor. Nature 396, 679–682 (1998). · DOI · Paper page
  89. Lee, S. P. et al. Dopamine D1 and D2 receptor coactivation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem. 24 May 2004 (doi: 10.1074/jbc.M401923200). · DOI · Paper page
  90. Kaupmann, K. et al. GABAB-receptor subtypes assemble into functional heteromeric complexes. Nature 396, 683–687 (1998). · DOI · Paper page
  91. Wreggett, K. A. & De Lean, A. The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland. Mol. Pharmacol. 26, 214–227 (1984).
  92. Park, P. S., Sum, C. S., Pawagi, A. B. & Wells, J. W. Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. Biochemistry 41, 5588–5604 (2002). · doi:10.1021/bi011746s
  93. Gripentrog, J. M. et al. Experimental evidence for lack of homodimerization of the G protein-coupled human N-formyl peptide receptor. J. Immunol. 171, 3187–3193 (2003). · doi:10.4049/jimmunol.171.6.3187
  94. Nelson, G. et al. An amino-acid taste receptor. Nature 416, 199–202 (2002). · DOI · Paper page
  95. He, L., Fong, J., von Zastrow, M. & Whistler, J. L. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108, 271–282 (2002). · DOI · Paper page
  96. Kunishima, M. et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407, 971–977 (2000). · DOI · Paper page
  97. Duthey, B. et al. A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor. J. Biol. Chem. 277, 3236–3241 (2002). · DOI · Paper page
  98. Salahpour, A., Angers, S. & Bouvier, M. Functional significance of oligomerization of G-protein-coupled receptors. Trends Endocrinol. Metab. 11, 163–168 (2000). · DOI
  99. Marshall, F. H. Heterodimerization of G-protein-coupled receptors in the CNS. Curr. Opin. Pharmacol. 1, 40–44 (2001). · DOI
  100. Wenzel-Seifert, K. & Seifert, R. Functional differences between human formyl peptide receptor isoforms 26, 98 and G6. Naunyn-Schmiedeberg's Arch. Pharmacol. 367, 509–515 (2003). · DOI
  101. McGavin, J. K. & Keating, G. M. Bisoprolol: a review of its use in chronic heart failure. Drugs 62, 2677–2696 (2002). · DOI
  102. Engelhardt, S., Grimmer, Y., Fan, G. -H. & Lose, M. J. Constitutive activity of the human β1-adrenergic receptor in β1-receptor transgenic mice. Mol. Pharmacol. 60, 712–717 (2001).
  103. Kvols, K. L. et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N. Engl. J. Med. 315, 663–666 (1986). · DOI · Paper page
  104. Katugampola, S. & Davenport, A. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system. Trends Pharmcol. Sci. 24, 30–35 (2003). · DOI
  105. Wise, A., Gearing, K. & Rees, S. Target validation of G-protein coupled receptors. Drug Discov. Today 7, 235–246 (2002). · DOI · Paper page
  106. Roques, B. P. Novel approaches to targeting neuropeptide systems. Trends Pharmacol. Sci. 21, 475–483 (2000). · DOI
  107. Strange, P. G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 53, 119–133 (2001).
  108. Gasparini, F., Kuhn, R. & Pin, J. P. Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr. Opin. Pharmacol. 2, 43–49 (2002). · DOI
  109. May, L. T. & Christopoulos, A. Allosteric modulators of G-protein-coupled receptors. Curr. Opin. Pharmacol. 3, 551–556 (2003). · DOI
  110. Schaffhauser, H. et al. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 64, 798–810 (2003). · DOI · Paper page
  111. Seifert, R. et al. Differential effects of Gsα splice variants on β2-adrenoceptor-mediated signaling. The β2-adrenoceptor coupled to the long splice variant of Gsα has properties of a constitutively active receptor. J. Biol. Chem. 273, 5109–5116 (1998). · DOI
  112. Wenzel-Seifert, K., Kelley, M. T., Buschauer, A. & Seifert, A. Similar apparent constitutive activity of human histamine H2-receptor fused to long and short splice variants of Gsα. J. Pharmacol. Exp. Ther. 299, 1013–1020 (2001).
  113. Gille, A. & Seifert, R. Co-expression of the β2-adrenoceptor and dopamine D1-receptor with Gsα proteins in Sf9 cells: limitations in comparison with fusion proteins. Biochim. Biophys. Acta 1613, 101–114 (2003). · DOI
  114. Fischer, J. A., Muff, R. & Born, W. Functional relevance of G-protein-coupled-receptor-associated proteins, exemplified by receptor-activity-modifying proteins (RAMPs). Biochem. Soc. Trans. 30, 455–460 (2002). · DOI
  115. Fujino, H. & Regan, J. W. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? Trends Pharmacol. Sci. 24, 335–340 (2003). · DOI
  116. Brady, A. E. & Limbird, L. E. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell. Signal. 4, 297–309 (2002). · DOI · Paper page
  117. Mallee, J. J. et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J. Biol. Chem. 277, 14294–14298 (2002). · DOI · Paper page
  118. Morfis, M., Christopoulos, A. & Sexton, P. M. RAMPs: 5 years on, where to now? Trends Pharmacol. Sci. 24, 596–601 (2003). · DOI
  119. Ango, F. et al. Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by Homer1 proteins and neuronal excitation. J. Neurosci. 20, 8710–8716 (2000). · DOI · Paper page
  120. Ango, F. et al. Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 411, 962–965 (2001). · DOI · Paper page
  121. Olson, W. C. et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73, 4145–4155 (1999). · DOI · Paper page
  122. Peter, J. C., Eftekhari, P., Billiald, P., Wallukat, G. & Hoebeke, J. scFv Single chain antibody variable fragment as inverse agonist of the β2-adrenergic receptor. J. Biol. Chem. 278, 36740–36747 (2003). · DOI
  123. Ogata, E. Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity. Cancer 88, 2909–2911 (2000). · doi:10.1002/1097-0142(20000615)88:12+<2909::aid-cncr5>3.0.co;2-7
  124. Kakonen, S. M. & Mundy, G. R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97 (Suppl. 3), 834–839 (2003). · DOI · Paper page
  125. Bowers, C. Y. Unnatural growth hormone-releasing peptide begets natural ghrelin. J. Clin. Endocrinol. Metab. 86, 1464–1469 (2001). · doi:10.1210/jcem.86.4.7431 · Paper page
  126. Mijares, A., Lebesgue, D., Wallukat, G. & Hoebeke, J. From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-β2-adrenoceptor antibody behave as antagonists. Mol. Pharmacol. 58, 373–379 (2000). · doi:10.1124/mol.58.2.373
  127. Shigemoto, R., Abe, T., Nomura, S., Nakanishi, S. & Hirano, T. Antibodies inactivating mGluR1 metabotropic glutamate receptor block long-term depression in cultured Purkinje cells. Neuron 12, 1245–1255 (1994). · DOI · Paper page
  128. Sillevis Smitt, P. et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. New Engl. J. Med. 342, 21–27 (2000). · DOI · Paper page
  129. Orgiazzi, J., Madec, A. M. & Ducottet, X. The role of stimulating, function-blocking and growth-blocking anti-TSH receptor antibodies (TRAbs) in GD, Hashimoto's disease and in atrophic thyroiditis. Ann. Endocrinol. 64, 31–36 (2003).
  130. Coffield, V. M., Jian, Q. & Su, L. A genetic approach to inactivating chemokine receptors using a modified viral protein. Nature Biotechnol. 21, 1321–1327 (2003). · DOI
  131. Dillon, S. B., Verghese, M. W. & Snyderman, R. Signal transduction in cells following binding of chemoattractants to membrane receptors. Virchows Arch. B Cell. Pathol. Incl. Mol. Pathol. 55, 65–80 (1988). · doi:10.1007/bf02896561
  132. Seifert, R. & Wenzel-Seifert, K. Defective Gi protein coupling in two formyl peptide receptor mutants associated with localized juvenile periodonttitis. J. Biol. Chem. 276, 42043–42049 (2001). · DOI
  133. Seifert, R. & Wenzel-Seifert, K. The human formyl peptide receptor as model system for constitutively active receptors. Life Sci. 73, 2263–2280 (2003). · DOI
  134. Rohrer, D. K. et al. Targeted disruption of the mouse β1-adrenergic receptor gene: developmental and cardiovascular effects. Proc. Natl Acad. Sci. USA 93, 7375–7380 (1996). · DOI · Paper page
  135. Roeske, W. R. & Wildenthal, K. Responsiveness to drugs and hormones in the murine model of cardiac ontogenesis. Pharmacol. Ther. 14, 55–66 (1981). · doi:10.1016/0163-7258(81)90010-3
  136. Murphy, P. M. Viral exploitation and subversion of the immune system through chemokine mimicry. Nature Immunol. 2, 116–122 (2001). · DOI · Paper page
  137. Turnbull, A. V. et al. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes 51, 2441–2449 (2002). · DOI
  138. Spiegel, A. M. Defects in G protein-coupled signal transduction in human disease. Annu. Rev. Physiol. 58, 143–170 (1996). · DOI · Paper page
  139. Inui, A. Neuropeptide gene polymorphisms and human behavioural disorders. Nature Rev. Drug Discov. 2, 986–998 (2003). · DOI
  140. Brown, E. & MacLeod, R. J. Extracellular calcium sensing and extracellular calcium signalling. Physiol. Rev. 81, 239–297 (2001). · DOI · Paper page
  141. Rosenthal, W., Antaramian, A., Gilbert, S. & Birnbaumer, M. Nephrogenic diagetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J. Biol. Chem. 268, 13030–13033 (1993). · DOI · Paper page
  142. Pollak, M. R. et al. Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor gene mutation. Nature Genet. 8, 303–307 (1994). · DOI · Paper page
  143. Daub, H., Ulrich-Weiss, F., Wallasch, C. & Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557–560 (1996). · DOI · Paper page
  144. Prenzel, N. et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB–EGE. Nature 402, 884–888 (1999). · DOI · Paper page
  145. Morello, J. P. & Bichet, D. G. Nephrogenic diabetes insipidus. Annu. Rev. Physiol. 63, 607–630 (2001). · DOI · Paper page
  146. Janovick, J. A., Maya-Nunez, G. & Conn, P. M. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J. Clin. Endocrinol. Metab. 87, 3255–3262 (2002). · doi:10.1210/jcem.87.7.8582 · Paper page
  147. Illing, M. E., Rajan, R. S., Bence, N. F. & Kopito, R. R. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem. 277, 34150–34160 (2002). · DOI · Paper page
  148. Corvilain, B., Van Sande, J., Dumont, J. E. & Vassart, G. Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin. Endocrinol. 55, 143–158 (2001). · DOI
  149. Sadée, W., Hoeg, E., Lucas, J. & Wang, D. Genetic variations in human G protein-coupled receptors: implications for drug therapy. AAPS PharmSci. 3, E22 (2001). · DOI
  150. O'Rahilly, S. Leptin: defining its role in humans by the clinical study of genetic disorders. Nutr. Rev. 60, S30–S34 (2002). · DOI
  151. Inui, A. Transgenic approach to the study of body weight regulation. Pharmacol. Rev. 52, 35–61 (2000).
  152. Willie, J. T., Chemelli, R. M., Sinton, C. M. & Yanagisawa, M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci. 24, 429–458 (2001). · DOI · Paper page
  153. Hosoda, K. et al. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color mice. Cell 79, 1267–1276 (1994). · DOI · Paper page
  154. Gao, J. L., Lee, E. J. & Murphy, P. M. Impaired bacterial host defense in mice lacking the N-formylpeptide receptor. J. Exp. Med. 189, 657–662 (1999). · DOI · Paper page
  155. Redrobe, J. P., Dumont, Y., Herzog, H. & Quirion, R. Characterization of neuropeptide Y, Y2 receptor knockout mice in two animal models of learning and memory processing. J. Mol. Neurosci. 22, 159–166 (2004). · DOI
  156. Arvanitakis, L., Geras-Raaka, E., Varma, A., Gershengorn, M. C. & Cesarman, E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385, 347–350 (1997). · DOI · Paper page
  157. Hunter, A. J., Nolan, P. M. & Brown, S. D. Towards new models of disease and physiology in the neurosciences: the role of induced and naturally occurring mutations. Hum. Mol. Genet. 9, 893–900 (2000). · DOI
  158. Christopoulos, A. & Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323–374 (2002). · DOI · Paper page
  159. Yanovski, S. Z. & Yanovski, J. A. Obesity. N. Engl. J. Med. 346, 591–602 (2002). · DOI · Paper page
  160. O'Dowd, B. et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136, 355–360 (1993). · DOI · Paper page
  161. Lee, D. K. et al. Discovery of a receptor related to the galanin receptors. FEBS Lett. 446, 103–107 (1999). · DOI · Paper page
  162. Quirion, R. & Weiss, A. S. Peptide E and other proenkephalin-derived peptides are potent κ opiate receptor agonists. Peptides 4, 445–449 (1983). · DOI
  163. Kniazeff, J., Galvez, T., Labesse, G. & Pin, J. P. No ligand binding in the GB2 subunit of the GABAB receptor is required for activation and allosteric interaction between the subunits. J. Neurosci. 22, 7352–7361 (2002). · DOI · Paper page
  164. Vassilatis, D. K. et al. The G protein-coupled receptor repertoires of human and mouse. Proc. Natl Acad. Sci. USA 100, 4903–4908 (2003). · DOI · Paper page
  165. Fujisawa, Y. et al. Orphan GPCR ligands related to obesity. Curr. Med. Chem. Central Nervous System Agents 3, 101–120 (2003). · doi:10.2174/1568015033477802
  166. Wise, A., Jupe, S. C. & Rees, S. The identification of ligands at orphan G-protein coupled receptors. Annu. Rev. Pharmacol. Toxicol. 44, 43–66 (2004). · DOI · Paper page
  167. Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656–660 (1999). · DOI · Paper page
  168. Inui, A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nature Rev. Neurosci. 2, 551–560 (2001). · DOI · Paper page
  169. König, M. et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383, 535–538 (1996). · DOI · Paper page
  170. Liu, C., Wilson, S. J., Kuei, C. & Lovenberg, T. W. Comparison of human, mouse, rat and guinea pig histamine H4 receptors reveal substantial pharmacological species variation. J. Pharmacol. Exp. Ther. 299, 121–130 (2001).
  171. Mason, D. A., Moore, J. D., Green, S. A. & Liggett, S. B. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J. Biol. Chem. 274, 12670–12674 (1999). · DOI · Paper page
  172. Wenzel-Seifert, K. & Seifert, R. Properties of Arg389–β1-adrenoceptor–Gsα fusion proteins: comparison with Gly389–β1-adrenoceptor–Gsα fusion proteins. Recept. Channels 9, 315–323 (2003). · doi:10.3109/713745179
  173. Weinshilboum, R. Pharmacogenetics: the future is here! Mol. Interventions 3, 118–122 (2003). · doi:10.1124/mi.3.3.118
  174. Taghzouti, K. et al. Cognition enhancing effects in young and old rats of pBC264, a selective CCK-B receptor agonist. Psychopharmacol. 143, 141–149 (1999). · DOI
  175. Neubig, R. R., Spedding, M., Kenakin, T. & Christopoulos, A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology. Pharmacol. Rev. 55, 597–606 (2003). · DOI · Paper page
  176. Kenakin, T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65, 2–11 (2004). · DOI · Paper page
  177. Milligan, G. & Bond, R. A. Inverse agonism and the regulation of receptor number. Trends Pharmacol. Sci. 18, 468–474 (1997). · doi:10.1016/s0165-6147(97)90685-4
  178. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Discov. 1, 198–210 (2002). · DOI · Paper page
  179. Kenakin, T. Efficacy at G-protein-coupled receptors. Nature Rev. Drug Discov. 1, 103–110 (2002). · DOI · Paper page
  180. Samama, P., Cottecchia, S., Costa, T. & Lefkowitz, R. J. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268, 4625–4636 (1993). · DOI · Paper page
  181. Weiss, J. M., Morgan, P. H., Lutz, M. W. & Kenakin, T. P. The cubic ternary complex receptor-occupancy model. I. Model description. J. Theor. Biol. 178, 151–167 (1996). · doi:10.1006/jtbi.1996.0014
  182. Weiss, J. M., Morgan, P. H., Lutz, M. W. & Kenakin, T. P. The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity. J. Theor. Biol. 178, 169–182 (1996). · doi:10.1006/jtbi.1996.0015
  183. Weiss, J. M., Morgan, P. H., Lutz, M. W. & Kenakin, T. P. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. J. Theor. Biol. 178, 381–397 (1996). · DOI · Paper page
  184. Offermanns, S. & Melvin, I. Simon. Gα15 and Gα16 couple a wide variety of receptors to phospholipase C. J. Biol. Chem. 270, 15175–15180 (1995). · DOI · Paper page
  185. Milligan, G. & Rees, S. Chimaeric Gα proteins: their potential use in drug discovery. Trends Pharmacol. Sci. 20, 118–124 (1999). · doi:10.1016/s0165-6147(99)01320-6
  186. Milligan, G. The use of receptor–G-protein fusion proteins for the study of ligand activity. Receptors Channels 8, 309–317 (2002). · doi:10.1080/10606820214639
  187. Molinari P. et al. Promiscuous coupling at receptor–Gα fusion proteins. The receptor of one covalent complex interacts with the α-subunit of another. J. Biol. Chem. 278, 15778–15788 (2003). · doi:10.1074/jbc.m300731200
  188. Kraulis, P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. App. Crystall. 24, 946–950 (1991). · DOI · Paper page
  189. Merritt, E. A. & Bacon, D. J. Raster3D: Photorealistic molecular graphics. Methods. Enzymol. 277, 505–524 (1997). · DOI · Paper page
  190. Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors. Nature Rev. Neurosci. 2, 274–286 (2001). · DOI · Paper page
  191. Arshavsky, V. Y., Lamb, T. D. & Pugh, E. N. Jr. G proteins and phototransduction. Annu. Rev. Physiol. 64, 153–187 (2002). · DOI · Paper page
  192. Blumer, J. R. & Lanier, S. M. Accessory proteins for G protein-signaling systems: activators of G protein signaling and other nonreceptor proteins influencing the activation state of G proteins. Receptor Channels 9, 195–120 (2003).
  193. Clapham, D. E. & Neer, E. J. G protein β-subunits. Annu. Rev. Pharmacol. Toxicol. 37, 167–203 (1997). · DOI · Paper page
  194. Dolphin, A. C. G protein modulation of voltage-gated calcium channels. Pharmacol. Rev. 55, 607–627 (2003). · DOI · Paper page
  195. Gilman, A. G. G proteins and regulation of adenylyl cyclase. Biosci. Reports 15, 65–97 (1995). · DOI · Paper page
  196. Hofmann, F., Lacinova, L. & Klugbauer N. Voltage-dependent calcium channels: from structure to function. Rev. Physiol. Biochem. Pharmacol. 139, 33–87 (1999). · DOI · Paper page
  197. Hollinger, S. & Hepler, J. R. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol. Rev. 54, 527–559 (2002). · DOI · Paper page
  198. Malbon, C. C. Insulin signalling: putting the 'G-' in protein–protein interactions. Biochem. J. 380, 11–12 (2004). · doi:10.1042/bj20040619
  199. Nürnberg, B. & Ahnert-Hilger, G. Potential roles of heterotrimeric G proteins of the endomembrane system. FEBS Lett. 389, 61–65 (1996). · DOI
  200. Nürnberg, B., Gudermann, T. & Schultz, G. Receptors and G proteins as primary components of transmembrane signal transduction. 2. G proteins: structure and function. J. Mol. Med. 73, 123–132 (1995). · DOI

200 of 210 shown

Cited by

See all 68

Metadata

Authors
Participants., T. N. R. D. D. G. Q., & Ellis, C.
Venue
Nature Reviews Drug Discovery
Published
2004-07
Volume
3
Issue
7
Pages
577-626
ISSN
  • 1474-1776
  • 1474-1784
Cited by
68
References
13
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The state of GPCR research in 2004. https://app.cochat.ai/papers/10.1038/nrd1458
The paper
Participants., T. N. R. D. D. G. Q., & Ellis, C. (2004). The state of GPCR research in 2004. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1458

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.